Question · Q3 2025
Shelby asked about the loss of exclusivity for Setrusumab, specifically regarding foundational IP expiring in 2028 and whether additional IP estate could extend protection beyond that timeframe.
Answer
Emil Kakkis, CEO and President, highlighted that orphan drug designation provides protection well past 2030. He also mentioned that biologics rarely face typical loss of exclusivity challenges and that additional IP related to discoveries in chronic treatment are being developed, positioning the program well for future protection.
Ask follow-up questions
Fintool can predict
RARE's earnings beat/miss a week before the call